Total Payments
$179,927
2024 Payments
$14,918
Companies
69
Transactions
750
Medicare Patients
5,183
Medicare Billing
$755,001
Payment Breakdown by Category
Other$141,775 (78.8%)
Consulting$15,956 (8.9%)
Food & Beverage$11,906 (6.6%)
Travel$9,672 (5.4%)
Education$617.63 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $141,775 | 60 | 78.8% |
| Consulting Fee | $15,956 | 10 | 8.9% |
| Food and Beverage | $11,906 | 630 | 6.6% |
| Travel and Lodging | $9,672 | 40 | 5.4% |
| Education | $617.63 | 10 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $43,139 | 31 | $0 (2024) |
| Amgen Inc. | $42,927 | 90 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $35,314 | 31 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $20,795 | 20 | $0 (2017) |
| TAIHO ONCOLOGY, INC. | $13,407 | 15 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $6,861 | 15 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $3,924 | 39 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,416 | 50 | $0 (2024) |
| AVEO Pharmaceuticals, Inc. | $1,831 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $975.42 | 57 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,918 | 73 | TAIHO ONCOLOGY, INC. ($13,407) |
| 2023 | $3,138 | 69 | AVEO Pharmaceuticals, Inc. ($1,815) |
| 2022 | $24,280 | 94 | GlaxoSmithKline, LLC. ($23,072) |
| 2021 | $13,979 | 84 | GlaxoSmithKline, LLC. ($12,615) |
| 2020 | $17,110 | 47 | GlaxoSmithKline, LLC. ($7,380) |
| 2019 | $45,672 | 134 | Amgen Inc. ($24,806) |
| 2018 | $31,292 | 110 | Takeda Pharmaceuticals U.S.A., Inc. ($15,558) |
| 2017 | $29,539 | 139 | Millennium Pharmaceuticals, Inc. ($20,795) |
All Payment Transactions
750 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Oncology | ||||||
| 12/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Oncology | ||||||
| 12/04/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.72 | General |
| 11/25/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: HEMATOLOGY | ||||||
| 11/21/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: Oncology | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: Oncology | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 10/21/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,290.00 | General |
| Category: Oncology | ||||||
| 10/21/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Travel and Lodging | In-kind items and services | $654.00 | General |
| Category: Oncology | ||||||
| 10/21/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Food and Beverage | In-kind items and services | $76.02 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Immunology | ||||||
| 10/17/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Consulting Fee | Cash or cash equivalent | $1,560.00 | General |
| Category: Oncology | ||||||
| 09/30/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Oncology | ||||||
| 09/18/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,630.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Food and Beverage | In-kind items and services | $115.27 | General |
| Category: Oncology | ||||||
| 09/18/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Travel and Lodging | Cash or cash equivalent | $40.20 | General |
| Category: Oncology | ||||||
| 09/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: DESMOID TUMORS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,327 | 2,592 | $865,755 | $212,283 |
| 2022 | 14 | 1,328 | 2,812 | $832,865 | $206,365 |
| 2021 | 12 | 1,337 | 2,369 | $658,745 | $183,601 |
| 2020 | 11 | 1,191 | 2,290 | $622,180 | $152,753 |
Total Patients
5,183
Total Services
10,063
Medicare Billing
$755,001
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 357 | 1,096 | $475,560 | $113,143 | 23.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 156 | 167 | $105,350 | $24,399 | 23.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 218 | 351 | $84,660 | $23,261 | 27.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 76 | 120 | $72,950 | $18,178 | 24.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 56 | 94 | $33,415 | $9,423 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $23,695 | $5,562 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 67 | 77 | $23,795 | $5,145 | 21.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 42 | 42 | $18,510 | $4,604 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $10,390 | $2,595 | 25.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 142 | 283 | $2,830 | $2,377 | 84.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 143 | 289 | $7,225 | $2,200 | 30.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 14 | 17 | $7,375 | $1,395 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 260 | 965 | $419,415 | $105,121 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 221 | 350 | $82,075 | $20,971 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 66 | 118 | $71,845 | $17,616 | 24.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 99 | 101 | $65,390 | $15,797 | 24.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 90 | 93 | $41,370 | $10,443 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 104 | 139 | $42,990 | $9,518 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 47 | 47 | $26,495 | $6,614 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 51 | 73 | $24,385 | $6,211 | 25.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $14,115 | $3,515 | 24.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 152 | 425 | $10,625 | $3,242 | 30.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 30 | 30 | $12,910 | $2,608 | 20.2% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 11 | 11 | $7,520 | $1,917 | 25.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 32 | 32 | $9,640 | $1,577 | 16.4% |
About Dr. Michael Levitt, M.D
Dr. Michael Levitt, M.D is a Hematology & Oncology healthcare provider based in Manasquan, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1891979381.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Levitt, M.D has received a total of $179,927 in payments from pharmaceutical and medical device companies, with $14,918 received in 2024. These payments were reported across 750 transactions from 69 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($141,775).
As a Medicare-enrolled provider, Levitt has provided services to 5,183 Medicare beneficiaries, totaling 10,063 services with total Medicare billing of $755,001. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Manasquan, NJ
- Active Since 12/20/2007
- Last Updated 10/22/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891979381
Products in Payments
- NINLARO (Drug) $56,094
- BLENREP (Biological) $41,653
- Kyprolis (Biological) $32,377
- INQOVI (Drug) $11,777
- XGEVA (Biological) $6,907
- BENDEKA (Drug) $6,832
- TAGRISSO (Drug) $2,984
- Kyprolis (Drug) $2,967
- OPDIVO (Biological) $2,609
- FOTIVDA (Drug) $1,831
- LONSURF (Drug) $1,630
- Cabometyx (Drug) $705.17
- CALQUENCE (Drug) $623.92
- TASIGNA (Drug) $325.37
- Lenvima (Drug) $308.73
- Ultomiris (Drug) $303.06
- XARELTO (Drug) $289.64
- KEYTRUDA (Biological) $251.10
- MYRISK (Device) $209.20
- Neulasta (Biological) $203.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Manasquan
Dr. Carl Henningson, M.d, M.D
Hematology & Oncology — Payments: $394,158
Hematology & Oncology $394,158
Dr. David Greenberg, Md, MD
Hematology & Oncology — Payments: $86,042
Hematology & Oncology $86,042
Dr. Peter Mencel, M.d, M.D
Hematology & Oncology — Payments: $28,378
Hematology & Oncology $28,378
Dr. William Lerner, M.d, M.D
Hematology & Oncology — Payments: $8,814
Hematology & Oncology $8,814
Ms. Madhurima Anne, Md, MD
Hematology & Oncology — Payments: $3,698
Hematology & Oncology $3,698
Arthur Topilow, M.d, M.D
Hematology & Oncology — Payments: $349.69
Hematology & Oncology $349.69